Inside the S-1: Risk Factors, MD&A, and Use of Proceeds

Introduction

The S-1 has dozens of sections, but three of them carry disproportionate weight. Risk factors articulate what could go wrong with the investment. MD&A is the management narrative on financial performance and the issuer's view of where the business is heading. Use of proceeds is the contractual commitment to investors about what the company will actually do with the IPO money. All three are scrutinized intensively by SEC reviewers during the comment-letter cycle, by sell-side and buy-side analysts during the roadshow, and by securities-litigation plaintiffs if the deal underperforms. This article walks through each section in detail: what it contains, how it gets drafted, what trade-offs the working group navigates, and the recurring patterns that distinguish strong sections from weak ones.

The risk factors section is the legal centerpiece of the S-1's investor disclosure. Required under Item 105 of Regulation S-K, it lists the "most significant" factors that make the investment speculative or risky. The section typically runs 30 to 80 pages and gets more SEC attention than almost any other part of the document.

Anatomy of a Single Risk Factor

A well-drafted risk factor follows a consistent structure: a sub-caption that summarizes the risk in a single sentence, followed by one to four paragraphs that explain the risk specifically as it relates to this issuer. Generic risk factors that could apply to any company are explicitly disfavored by the SEC under the 2020 Regulation S-K amendments. Risk factors that say "We may face increased competition" without explaining how this issuer's competitive dynamic is shifting will draw an SEC comment to make the language specific.

The Categorization Convention

Risk factors are typically grouped into four to six categories: business and operational risks, regulatory and legal risks, financial and accounting risks, risks related to the offering, and risks related to ownership of the common stock. Each category contains five to twenty individual risk factors, depending on the issuer's complexity. The order within each category follows materiality: the most significant risks come first.

The 15-Page Summary Trigger

The 2020 amendments added a new disclosure requirement: if the risk factors section exceeds 15 pages, the issuer must include a summary risk factors section (no more than two pages) in the prospectus summary, presenting the principal risks as concise, bulleted or numbered statements summarizing each principal risk. Most IPO S-1s exceed the 15-page threshold easily, so summary risk factors are now standard.

The Recurring Risk Factor Categories

Across nearly every IPO S-1, certain risk-factor categories recur. Business risks include customer concentration, key supplier dependence, technology obsolescence, dependence on key personnel, and competition. Regulatory risks include sector-specific regulation, changes in law, antitrust scrutiny, and environmental liability. Financial risks include leverage, liquidity, controls, and tax exposure. Stock-specific risks include lockup expiration, voting structure (for dual-class issuers), and the trading volatility characteristic of newly-public companies. Each category has standard language patterns that sector-specialist counsel and bankers recognize immediately.

MD&A (Item 303 of Regulation S-K) is the narrative section that translates the financial statements into management's perspective on the business. It is the section sell-side analysts read most carefully when initiating coverage post-IPO, and it is the section the SEC most consistently comments on through review cycles.

Three Required Areas: Operations, Liquidity, Trends

MD&A addresses three core areas: results of operations (what happened in the historical periods), liquidity and capital resources (the issuer's cash flow and balance-sheet condition), and known trends and uncertainties (forward-looking commentary on what's expected). Most issuers structure MD&A to mirror the financial statements, walking through revenue, gross margin, operating expenses, and bottom-line profitability for each year and stub period covered.

The Drafting Tension

MD&A is the section where the equity story most directly shapes the disclosure. Issuers want the MD&A to read favorably, framing growth as durable and challenges as manageable. Counsel and the SEC want the MD&A to be balanced, addressing both positive and negative trends. The bankers play a useful intermediary role: they understand what investors will scrutinize, what management's framing implies, and where the SEC is likely to push back. Strong MD&A drafting incorporates that intermediary perspective rather than letting either the marketing or the legal pole win the section outright.

Key Performance Indicators

Most modern S-1s include a discussion of key performance indicators (KPIs) within MD&A: revenue retention, customer counts, ARR growth, same-store sales, capacity utilization, or other metrics specific to the business model. KPI disclosure is heavily scrutinized because once disclosed, issuers must continue to report the KPIs in subsequent quarterly filings, and the metrics need to be consistent with how management actually runs the business. Working groups think carefully about which KPIs to disclose, because the disclosure becomes a long-term commitment.

Item 303 of Regulation S-K

The SEC rule that prescribes the content of Management's Discussion and Analysis (MD&A) in registration statements and periodic filings. Item 303 requires disclosure of liquidity, capital resources, results of operations, and known trends and uncertainties that would have a material effect on the issuer's financial condition or results. The standard is one of the most extensive in securities law, and SEC reviewers consistently focus on whether MD&A addresses every required element with sufficient specificity.

The Forward-Looking Section

The "known trends and uncertainties" portion of MD&A is forward-looking and gets particular SEC attention. Issuers must disclose any known trend, demand, commitment, event, or uncertainty that has had or is reasonably likely to have a material favorable or unfavorable impact on revenues or income. Issuers cannot stay silent on material forward-looking trends; the SEC routinely comments to push for fuller forward-looking disclosure when management's section reads as if everything is steady.

Use of proceeds is one of the shortest sections in the S-1 (typically two to three pages) but one of the most consequential. It states what the company will do with the money raised in the offering, with enough specificity that investors can evaluate the deployment plan.

The Categories and the Specificity Trade-Off

A typical use of proceeds section breaks the IPO proceeds into three to six categories: debt paydown (if applicable), capital expenditure, R&D, working capital, M&A capacity, and general corporate purposes. Specific dollar amounts get attached to each category where the issuer has firm plans; less specific language ("a portion of the proceeds") is used where plans are flexible. The mix between specific and flexible disclosure is a meaningful drafting decision: too specific and the issuer is locked into the disclosed plan, too flexible and the SEC will push for more detail.

Item 105 of Regulation S-K

The SEC rule that requires registrants to disclose the most significant risk factors that make an investment in the issuer or the offering speculative or risky. Item 105 was amended in 2020 to require risk factors to be organized logically, presented under sub-captions that summarize each risk in a sentence, and free of generic language that could apply to any company. If the risk-factors section exceeds 15 pages, Item 105 also requires a summary risk-factors section (no more than two pages) in the prospectus summary, presented as concise, bulleted or numbered statements summarizing each principal risk. Item 105 is one of the SEC's most enforced disclosure rules during S-1 review.

Primary Versus Secondary Proceeds

If the offering includes a secondary component (existing shareholders selling stock alongside the company), the secondary proceeds go to the selling shareholders rather than to the issuer. The S-1 must distinguish between primary and secondary proceeds and explain that the issuer will not receive any of the secondary money. This distinction matters because the use-of-proceeds section governs only the primary portion; what selling shareholders do with their money is their business.

The Recurring Categories

Across IPOs, certain use-of-proceeds categories recur with predictable frequency. Sponsor-backed issuers almost always include a debt-paydown component (refinancing the LBO debt). Growth-stage technology issuers include heavy general-corporate-purposes language plus working capital. Biotech issuers include detailed R&D allocations with named pipeline candidates. The category mix tells investors something about the issuer's stage and strategy.

Risk factors, MD&A, and use of proceeds are not independent. Each one carries information that should be consistent with the others, and inconsistencies between them are one of the most common SEC comment categories.

The Consistency Standard

If a risk factor describes customer concentration as a material risk, the MD&A should disclose customer-concentration metrics in the historical periods and any concentration trends. If MD&A discusses the issuer's leverage as a constraint on growth, the use of proceeds should reflect debt paydown if proceeds will reduce leverage. The SEC routinely cross-references the three sections during review and pushes for consistency where gaps appear.

The Investor Reading Pattern

Sophisticated institutional investors typically read the prospectus summary first, then the MD&A, then the risk factors, then the financial statements, then the business description. Use of proceeds is read after MD&A as part of evaluating the financial trajectory. The order matters because each section frames how the next one is read: a strong MD&A makes a long risk-factors section feel manageable; a weak MD&A makes the same risk factors feel ominous.

The bankers' role across these three sections is consistent but section-specific. On risk factors, bankers contribute insight into what investors will perceive as material and which risk language sounds defensible versus alarming. On MD&A, bankers contribute the equity-story coherence that ties the financial narrative to the marketing thesis, plus a reality check on whether the management framing will hold up to investor questions. On use of proceeds, bankers contribute the expectation of how investors will read the deployment plan, particularly on sponsor-backed deals where the debt-paydown component shapes the post-IPO leverage story.

The Iteration Cycle

Each section goes through multiple iterations across drafting sessions, SEC comments, and pre-roadshow refinements. Risk factors often undergo the most iterations because every diligence finding produces a candidate risk factor and the working group has to decide which findings rise to disclosure. MD&A undergoes substantial iteration because the financial story evolves as new periods close and KPI definitions get refined. Use of proceeds typically settles earlier in the process but gets revisited whenever the deal size or sponsor secondary component changes.

The three sections above receive the most attention, but several others matter enough that bankers and counsel devote real drafting energy to them.

The Prospectus Summary

The prospectus summary (the "box") is the section most likely to be the only part of the S-1 that some investors read. It distills the issuer's investment case into 10 to 30 pages and is one of the most heavily-edited parts of the document. The summary's opening paragraph is the closest the S-1 ever comes to an elevator pitch for the company, and its drafting is owned by the lead-left bookrunner's coverage banker as much as by counsel. A strong prospectus summary reads as a coherent investment thesis with the supporting evidence visible; a weak one reads as a list of facts without a unifying argument.

Principal Stockholders

The principal stockholders table shows who owns the company before and after the IPO, including pre-IPO sponsors, founders, executives, and selling shareholders in the offering. The table is closely read by investors evaluating sponsor exit dynamics, founder commitment, and post-IPO insider concentration. Issuers with dual-class stock structures use this section to show how voting power concentrates, often differently from economic ownership. The disclosures here have downstream consequences for the post-IPO governance narrative.

Plan of Distribution

Plan of distribution describes the offering mechanics: the gross spread, the over-allotment option, the lockup, the syndicate composition, and any non-standard arrangements. This section is owned by underwriter's counsel and is the place where unusual structural decisions (a directed share program, a non-standard greenshoe size, an extended lockup) get disclosed. Investors comparing one IPO against another often read this section closely to understand how the offering economics compare.

Description of Capital Stock

The description of capital stock walks through every class of stock the issuer will have outstanding after IPO, the rights attached to each class, the voting structure, dividend rights, and conversion features. For dual-class issuers (founder-controlled technology companies are the most common pattern), this section discloses the specific super-voting structure, any sunset provisions, and how the voting power converts to one-share-one-vote over time. Description of capital stock is dense legal drafting but it is what governs post-IPO shareholder rights.

The SEC's comment letters typically include comments on each of the major sections, and the working group's response shapes how the disclosure looks at effectiveness.

Risk Factor Comments

Risk-factor comments cluster around two patterns: language too generic to satisfy Item 105's specificity requirement, and risks that show up in the diligence findings or the financial statements but are missing from the risk factors section. The working group responds by either revising the risk language or explaining (in writing) why the specific risk does not warrant disclosure. SEC reviewers occasionally accept the latter response but more often push back and require disclosure.

MD&A Comments

MD&A comments cluster around forward-looking trends that the SEC believes deserve fuller discussion, KPI disclosure that needs more detail, and inconsistencies with the financial statements. Working groups respond with substantive revisions to the section, often expanding MD&A by several pages in a single round of response. The SEC's MD&A comments are why MD&A is typically the section that grows the most through the comment-cycle process.

Use of Proceeds Comments

Use-of-proceeds comments are usually the least frequent because the section is the shortest and most procedural. When they arise, they usually push for more specificity ("explain in more detail what 'general corporate purposes' includes") or consistency with the rest of the document. SEC reviewers will sometimes also press the issuer on whether the disclosed deployment plan is actually achievable in the time frame implied by the language, particularly when the planned uses include large M&A or capital expenditure that the issuer has not previously executed at the proposed scale.

How the Comment Cycle Shapes the Final Document

By the time an S-1 becomes effective, it has typically grown by 10 to 30 pages from the first submission, with the growth concentrated in MD&A and risk factors. The final document looks meaningfully more comprehensive than the first version because the SEC review process pushes systematically toward fuller disclosure. The bankers and counsel who guide the issuer through this evolution understand from experience that the final S-1 is usually a better document than the first draft, even when the comment cycle felt painful in real time.

Risk factors, MD&A, and use of proceeds are where the substance of the IPO actually lives in the document; everything else either sets context or implements mechanics. How the document moves from first submission to effectiveness is the subject of the SEC review process and the JOBS Act EGC pathway.